Alexion Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Alexion Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#183 of 15,742 sponsors by registered trial count).
Alexion Pharmaceuticals: 162 sponsored US clinical trials, 17 recruiting.
Alexion Pharmaceuticals sponsors 162 registered US clinical trials on ClinicalTrials.gov, 17 of them currently recruiting, and 93 completed. 45 of these trials are in Phase 3-4 (later-stage) and 90 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Paroxysmal Nocturnal Hemoglobinuria, with 5 trials.
Top-decile sponsor footprint
Alexion Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#183 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
93 of 129 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
162 total, page 2 of 4
Study of Radiolabeled ALXN2050 in Healthy Adult Males
NCT04609670
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
NCT04564339
Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)
NCT04469465
A Study of the Cardiac Effects of ALXN2050 in Healthy Adults
NCT04660890
Study of Ravulizumab in Pediatric Participants With HSCT-TMA
NCT04557735
Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840
NCT04422431
Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants
NCT04526210
Study of the Metabolism of Danicopan in Healthy Adults
NCT04609696
Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
NCT04573309
A Study of the Cardiac Effects of ALXN1840 in Healthy Adults
NCT04560816
Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.
NCT04526197
A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants
NCT04551586
Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
NCT04369469
An Efficacy and Safety Study of Ravulizumab in ALS Participants
NCT04248465
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
NCT04304144
A Study of the Effects of Food and Age on Danicopan
NCT04551599
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
NCT04155424
A Drug Interaction Study of ACH-0145228
NCT04709081
An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
NCT04201262
Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)
NCT04195763
A Drug Interaction Study of Danicopan
NCT04709094
Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor
NCT03661528
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
NCT03920293
Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
NCT03748823
US Selumetinib Registry
NCT05683678
A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
NCT03759366
A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults
NCT05109390
A Study of the Cardiac Effects of Danicopan in Healthy Adults
NCT05016206
Study Evaluating Betrixaban in Pediatric Participants
NCT03346083
A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471
NCT03459443
A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
NCT03369236
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab
NCT03472885
Study of Danicopan in Participants With Hepatic Impairment
NCT03555539
A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria
NCT03406507
Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
NCT03403205
Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction
NCT04935294
A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)
NCT03075878
Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT03131219
A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)
NCT03075904
ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
NCT03056040
Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT02949128
ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT02946463
Study of Samalizumab in Patients With Advanced Cancer
NCT02987504
Screening for Lysosomal Acid Lipase Deficiency
NCT02926872
Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)
NCT02797821
The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment
NCT02763215
Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid
NCT02226146
Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment
NCT02614898
A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)
NCT02329327
Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
NCT02324049
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 43 |
| Phase 2 | 47 |
| Phase 3 | 42 |
| Phase 4 | 3 |
What is open in the Alexion Pharmaceuticals pipeline
17 recruiting of 162 indexed (10% open); 93 completed (57%).
Phase mix: 45 late (III/IV) vs 90 early (I/II) (early-phase heavy).
Top condition: Paroxysmal Nocturnal Hemoglobinuria (5 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Alexion Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 162 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Alexion Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 162 trials (± recruiting share)
- University of Vermont · 162 trials · 9% recruiting
- Temple University · 163 trials · 13% recruiting
- Tufts University · 163 trials · 6% recruiting
- Wayne State University · 163 trials · 13% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Vertex Pharmaceuticals Incorporated · 10% recruiting · 191 trials
- Bastyr University · 11% recruiting · 19 trials
- Corewell Health West · 11% recruiting · 38 trials
- Ethicon · 11% recruiting · 38 trials
Related
What to do with this Alexion Pharmaceuticals page
162 registered trials is a research-attention snapshot, not an endorsement of Alexion Pharmaceuticals or any single study.
- 17 of Alexion Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Paroxysmal Nocturnal Hemoglobinuria is the condition Alexion Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Paroxysmal Nocturnal Hemoglobinuria trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Alexion Pharmaceuticals pipeline card: 162 registered trials from official public datasets.Report a data error.